ccr9

Vercirnon (Traficet-EN) 是可口服的选择性 CCR9拮抗剂，可抑制 CCR9 介导的 Molt-4 细胞上 Ca2+移动和趋化性，用于炎症性肠病的研究。

Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9 . Vercirnon sodium inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC 50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC 50 s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC 50 values of 2.8 and 2.6 nM, respectively.

MLN3126 是一种口服具有活力的强效 CCR9 拮抗剂。 MLN3126 抑制 CCL25 诱导的钙动员 (calcium mobilization) 和小鼠初级胸腺细胞趋化 (chemotaxis) (IC50: 6.3 nM)。